The
following table represents common stock equivalents that were excluded from the computation of diluted loss per share for the three and
six months ended June 30, 2026 and 2025, because the effect of their inclusion would be anti-dilutive:
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
Three Months Ended June 30, | | |
Six Months Ended June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
| | |
| | |
| | |
| |
| Restricted common stock grants | |
| 4,130,629 | | |
| - | | |
| 4,130,629 | | |
| - | |
| Series A convertible preferred stock (as converted to common) | |
| 3,804,348 | | |
| - | | |
| 3,804,348 | | |
| - | |
| Total anti-dilutive shares excluded | |
| 7,934,977 | | |
| - | | |
| 7,934,977 | | |
| - | |
|